Fundamentals of Research in Imaging and Theranostics Part 2
2025-03-01 08:00 - 2027-03-30 17:00 (Europe/Vienna)
UEMS EACCME has granted the accreditation of 4.5 CME credits for this event.

This online course is part of a longer line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation, as well as the design, conductance and reporting of clinical research trials, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

For phase I/II clinical studies with radiopharmaceuticals to understand:

The principles of technical realisation of the study including assessment of safety of investigational medicinal product

The statistical considerations, including the estimation of number of subjects to be enrolled

The regulatory requirements for performing clinical studies with radiopharmaceutical with special focus on diagnostic radiopharmaceuticals and to summarise the particularities of these studies

The ethical and medical considerations in common and vulnerable populations

The principles of preparing the clinical study protocol

The objectives, endpoints and outcome measures

The principles of patient selection, inclusion and non-inclusion criteria

The principles of establishment of the standard of truth, the role of the comparator, superiority/non-inferiority/equivalence(?) studies) & practical examples

Target Audience

Personnel involved in designing and/or performing phase I/II clinical research with diagnostic radiopharmaceuticals (e.g. nuclear medicine physicians, pharmacists, physicists, nurses, technologist, administrative staff).

Personnel involved in assessment of the ethical, medical and methodologic aspects of phase I/II research protocols with diagnostic radiopharmaceuticals.

All professionals interested in phase I/II clinical research with diagnostic radiopharmaceuticals

Faculty

Chiara GranaSpeaker

Bart de KeizerSpeaker

Caroline StokkeSpeaker

Jean-Noel TalbotSpeaker

Luisa Roldao PereiraSpeaker

John Andrei IagaruSpeaker

Sona BalogovaSpeaker

Highlights of Focus Meeting 6: Shaping the Future of Breast Cancer Care with Molecular Imaging
2025-04-25 00:00 - 2026-04-25 23:59 | Online
Breast cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death in women worldwide. Despite significant advancements in imaging and treatment, clinical practice remains heterogeneous across institutions and disciplines. Molecular imaging has a pivotal role in breast cancer care, from diagnosis to recurrence assessment. To address these discrepancies and define the future direction of imaging in breast cancer, the European Association of Nuclear Medicine (EANM) devoted its 6th Focus Meeting to this topic, under the following motto “Shaping the Future of Breast Cancer Care with Molecular Imaging”.

The aims of this project were:

To define the role of imaging in breast cancer, particularly the utility of nuclear medicine techniques in different clinical settings (including initial systemic staging, assessment of response to therapy, and detection of recurrence).

To reach a multidisciplinary consensus on the current state of the art in nuclear medicine imaging in breast cancer.

To generate expert recommendations on how best to guide professionals in their clinical decisions, beyond the existing guidelines.

To identify knowledge gaps and topics with lack of scientific evidence for potential future studies.

The recordings in this course are sponsored by Novartis.

Register nowEnrol in the online course now for free! Register now

Faculty

Isabel T. RubioSpeaker

Frederique Penault LlorcaSpeaker

Thiemo van NijnattenSpeaker

Elizabeth DibbleSpeaker

Tessa BuckleSpeaker

Katja Pinker DomenigSpeaker

Sofia Carrilho-VazSpeaker

Martina Bašić-KoretićSpeaker

David GroheuxSpeaker

Gary UlanerSpeaker

Geraldine GebhartSpeaker

Wolfgang WeberSpeaker

Valeria RomeoSpeaker

Alessandra GennariSpeaker

Karolien GoffinSpeaker

Nadia HarbeckSpeaker

Pascal BaltzerSpeaker

Michel van KruchtenSpeaker

Gary Cook Speaker

Paola Anna ErbaSpeaker

Joana M RibeiroSpeaker

Carolien SchröderSpeaker

Ritse MannSpeaker

Philipp BackhausSpeaker

Malene Gubbe Hildebrand Speaker

Fatima CardosoSpeaker

Antoinette AttardSpeaker

Francesco SchnettiniSpeaker

Sofia RiveraSpeaker

Event Overview

Bringing Alpha Therapies into Clinical Practice
2025-10-30 08:00 - 2027-11-30 17:00 | Online
UEMS EACCME has granted the accreditation of 3 CME credits for this event.

This online course offers a comprehensive introduction to alpha therapy in nuclear medicine, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available, describing all important steps required for production and radiopharmaceutical development. The advantages, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials, with the best yet to come. Dosimetry will play a pivotal role in this course, underlying its role in clinical practice. Finally, The Alphamet project will be presented, allowing you to get updated with the latest insights from Theranostics.

RPH

Targeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment, harnessing the potent, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT, highlighting its exceptional potency, unique ability to overcome radio-resistance, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides, the biological advantages of short-range high-energy emissions, and the complex challenges involved in the development, production, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology.

Oncology

In this part of the course, participants will explore the main advantages of alpha-emitting radionuclides in oncology, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials, providing valuable knowledge on the future direction of this rapidly evolving field.

Dosimetry

Participants will begin by exploring the basic concepts of dosimetry with alpha emitters, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition, the course presents the Alphamet project, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

To gain an overview of the main advantages of Alpha-radionuclides

To learn about the challenges of alpha emitters, complex production; transport issues, waste management and handling

To get insights on radiobiology: radiotoxicity & effectiveness

To have a comprehensive review of research candidates

To provide an overview of the main advantages when using Alpha-Therapy in clinical practice

To learn about the clinical challenges when using Alpha-Therapy

To get insights into current and future trials focusing on Alpha-Therapy

To learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters

To learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters

To learn on the Alphamet project, which addresses the unique and unmet metrological challenges of targeted alpha therapies, contributing to their safe and optimised implementation into routine clinical practice

Target Audience

Nuclear medicine physicians, radiologists, medical oncologists, urologists, radiation oncologists, medical physicists, biologists, researchers

Radiochemists, radiopharmacists, physicists, medical physicists, biologists

ProgrammeClick to see the full event programme. View the Programme

Faculty

Dana NiculaeSpeaker

Emma AnaheimSpeaker

Janke KleyhansSpeaker

Marianna TosatoSpeaker

Wolfgang FendlerSpeaker

Mathias ZacherlSpeaker

Pablo Mínguez GabiñaSpeaker

Mike SathekgeSpeaker

Daniela Oprea-LagerSpeaker

Ana Denis-BacelarSpeaker

Joe O’SullivanSpeaker

myEANM accountLog into your myEANM account or create a new one.

ESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations

Enroll yourselfFind your desired course under ‘Online Courses’

Enjoy!Once enrolled, you get full access to the course contents on the ESMIT eLearning platform

Event Overview
